QZQinghao Zhang

Qinghao Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinghao Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Changsheng Liu

    Engineering Research Center for Biomedical Materials of the Ministry of Education, East China University of Science and Technology, Shanghai, 200237, PR China

    1 shared publication
  • Dandan Long

    State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China

    1 shared publication
  • Fuwei Zhu

    State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China

    1 shared publication
  • Jing Wang

    The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China

    1 shared publication
  • Kai Dai

    The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, People’s Republic of China

    1 shared publication
  • Shuang Zhang

    State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China

    1 shared publication

Latest Publications

  • A BMP-2–triggered in vivo osteo-organoid for cell therapy

    by Kai Dai, Qinghao Zhang, Shunshu Deng, Yuanman Yu, Fuwei Zhu, Shuang Zhang, YuanZhong Pan, Dandan Long, Jing Wang, Changsheng Liu

    Cell therapies and regenerative medicine interventions require an adequate source of therapeutic cells. Here, we demonstrate that constructing in vivo osteo-organoids by implanting bone morphogenetic protein–2–loaded scaffolds into the internal muscle pocket near the femur of mice supports the growth and subsequent harvest of therapeutically useful cells including hematopoietic stem/progenitor cells (HSPCs), mesenchymal stem cells (MSCs), lymphocytes, and myeloid cells. Profiling of the in vivo osteo-organoid maturation process delineated three stages—fibroproliferation, osteochondral differentiation, and marrow generation—each of which entailed obvious changes in the organoid structure and cell type distribution. The MSCs harvested from the osteochondral differentiation stage mitigated carbon tetrachloride (CCl 4 )–induced chronic liver fibrosis in mice, while HSPCs and immune cells harvested during the marrow generation stage rapidly and effectively reconstituted the impaired peripheral and solid immune organs of irradiated mice. These findings demonstrate the therapeutic potentials of in vivo osteo-organoid–derived cells in cell therapies.